Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's disease.
作者信息
Reiderer P, Reynolds G P
出版信息
Br J Clin Pharmacol. 1980 Jan;9(1):98-9. doi: 10.1111/j.1365-2125.1980.tb04805.x.
Abstract
摘要
相似文献
1
Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's disease.司来吉兰是一种用于帕金森病长期治疗的脑单胺氧化酶B（MAO-B）选择性抑制剂。
Br J Clin Pharmacol. 1980 Jan;9(1):98-9. doi: 10.1111/j.1365-2125.1980.tb04805.x.
2
Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.单胺氧化酶B抑制剂的药理学：（-）司来吉兰在帕金森病中的作用方式。
J Neural Transm Suppl. 1986;22:91-105.
3
Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.用左旋司来吉兰治疗的帕金森病患者大脑中的单胺氧化酶活性和单胺代谢
J Neurochem. 1986 May;46(5):1359-65. doi: 10.1111/j.1471-4159.1986.tb01747.x.
4
(-)Deprenyl in the treatment of Parkinson's disease.（-）司来吉兰治疗帕金森病。
Clin Neuropharmacol. 1982;5(2):195-230. doi: 10.1097/00002826-198205020-00004.
5
Monoamine oxidase activity during (--)-deprenil therapy: human brain post-mortem studies.（-）-去甲丙咪嗪治疗期间的单胺氧化酶活性：人脑尸检研究
Adv Biochem Psychopharmacol. 1978;19:377-82.
6
Deprenyl (selegiline): the history of its development and pharmacological action.司来吉兰（丙炔苯丙胺）：其研发历程与药理作用
Acta Neurol Scand Suppl. 1983;95:57-80. doi: 10.1111/j.1600-0404.1983.tb01517.x.
7
The effect of deprenyl (selegiline) on intra- and extraneuronal dopamine oxidation.丙炔苯丙胺（司来吉兰）对神经元内和神经元外多巴胺氧化的影响。
Acta Neurol Scand Suppl. 1983;95:81-5. doi: 10.1111/j.1600-0404.1983.tb01518.x.
8
[History of deprenyl--the first selective inhibitor of monoamine oxidase type B].[司来吉兰的历史——首个单胺氧化酶B型选择性抑制剂]
Vopr Med Khim. 1997 Nov-Dec;43(6):482-93.
9
Deprenyl (selegiline) in the treatment of Parkinson's disease.司来吉兰治疗帕金森病
Acta Neurol Scand Suppl. 1983;95:103-5. doi: 10.1111/j.1600-0404.1983.tb01522.x.
10
Deprenyl as prophylaxis against Parkinson's disease?司来吉兰作为帕金森病的预防药物？
Clin Neuropharmacol. 1988 Dec;11(6):500-11. doi: 10.1097/00002826-198812000-00003.
引用本文的文献
1
Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.司来吉兰用于左旋多巴治疗的帕金森病患者反应波动的管理
J Neurol Neurosurg Psychiatry. 1980 Nov;43(11):1016-21. doi: 10.1136/jnnp.43.11.1016.
本文引用的文献
1
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.单胺氧化酶-B抑制剂司立吉林增强左旋多巴治疗后的抗运动不能作用。
J Neural Transm. 1975;36(3-4):303-26. doi: 10.1007/BF01253131.
2
Dopamine is a monoamine oxidase B substrate in man.多巴胺是人体内单胺氧化酶B的底物。
Nature. 1977 Jan 6;265(5589):80-1. doi: 10.1038/265080a0.
3
Recent observations on the clinical pharmacology of (-)deprenyl.关于（-）司来吉兰临床药理学的近期观察
J Neural Transm. 1978;43(3-4):245-51. doi: 10.1007/BF01246961.
4
On the mode of action of L-deprenyl in the human central nervous system.关于L-司来吉兰在人类中枢神经系统中的作用方式
J Neural Transm. 1978;43(3-4):217-26. doi: 10.1007/BF01246958.
5
Deprenyl is metabolized to methamphetamine and amphetamine in man.在人体中，司来吉兰会代谢为甲基苯丙胺和苯丙胺。
Br J Clin Pharmacol. 1978 Dec;6(6):542-4. doi: 10.1111/j.1365-2125.1978.tb00883.x.
6
Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'.人服用司来吉兰：一种无“奶酪效应”的选择性单胺氧化酶B抑制剂。
Psychopharmacology (Berl). 1978 Apr 14;57(1):33-8. doi: 10.1007/BF00426954.
7
Deprenyl in Parkinson's disease.
Lancet. 1977 Oct 15;2(8042):791-5. doi: 10.1016/s0140-6736(77)90725-5.
8
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.“美多芭”与左旋司来吉兰联合治疗帕金森病的意义。一项长期研究。
Lancet. 1977 Feb 26;1(8009):439-43. doi: 10.1016/s0140-6736(77)91940-7.
Zotero 插件